FIELD: medicine; oncology.
SUBSTANCE: group of inventions can be used to produce a vaccine composition for treating cancer characterized by Her2/neu expression or overexpression. Vaccine composition contains: (1) an adjuvant which is a water-in-oil emulsion which is Montanide; and (2) at least one fused peptide conjugated with a carrier protein, wherein the carrier protein is a variant of diphtheria toxin CRM197 having a sequence of SEQ ID NO: 61, and where at least one fused peptide contains two or more non-adjacent B-cell epitopes Her2/neu, selected from a group consisting of SEQ ID NO: 1–7. Group of inventions also includes pharmaceutical compositions and methods of using vaccine and/or pharmaceutical compositions for treating or preventing cancer, characterized by Her2/neu expression or overexpression, in a patient in need thereof.
EFFECT: using the given group of inventions enables to obtain an amplified humoral immune response by stimulating the production of antibodies specific for B-cell epitopes and Her2/neu, when said peptides are conjugated with CRM-197, and a water-in-oil emulsion.
18 cl, 23 dwg, 9 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SACCHARIDE CONJUGATED VACCINES | 2005 |
|
RU2454244C2 |
| NUCLEIC ACID SYNTHETIC MOLECULE (VERSIONS), MAMMAL CELL EXPRESSION VECTOR, MAMMAL HOST CELL AND METHOD OF EXPRESSING ANTIGEN PROTEIN OF HUMAN EPIDERMAL GROWTH FACTOR-2 (HER2/neu) OR SHORTENED FORM THEREOF | 2004 |
|
RU2397249C2 |
| IMMUNOGENIC COMPOSITIONS | 2011 |
|
RU2608905C2 |
| IMMUNOGEN PEPTIDE AGAINST GROUP A STREPTOCOCCI | 2018 |
|
RU2775621C2 |
| IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENS | 2010 |
|
RU2536981C9 |
| POLYSACCHARIDE-PROTEIN CONJUGATE POLYSACCHARIDE-PROTEIN FOR INDUCING IMMUNE RESPONSE AND PROTECTION AGAINST Staphylococcus aureus INFECTION, METHODS OF CONJUGATE OBTAINING (VERSIONS), CONJUGATE-CONTAINING COMPOSITION AND METHODS OF INDUCING IMMUNE RESPONSE AND PREVENTION OF Staphylococcus aureus INFECTION | 2010 |
|
RU2531234C2 |
| PLASMID pVAX-RBD DNA MATRIX OF mRNA-RBD MOLECULES, OBTAINED USING THE pVAX - RBD DNA MATRIX, PROVIDING THE SYNTHESIS AND SECRETION OF THE RBD PROTEIN SARS-CoV 2 IN MAMMALIAN CELLS AND A COMPLEX IN THE FORM OF NANOPARTICLES CONTAINING mRNA-RBD MOLECULES THAT INDUCE SARS-CoV-SPECIFIC ANTIBODIES WITH VIRAL NEUTRALIZING ACTIVITY | 2021 |
|
RU2754230C1 |
| USE OF PEPTIDE THAT ENHANCES SECRETION OF SOMATOTROPIC HORMONE AS VACCINE ADJUVANT | 2017 |
|
RU2768134C2 |
| METHOD FOR AUTOANTIGEN VACCINATION IN A HUMAN PATIENT | 2016 |
|
RU2734924C2 |
| FUSED PROTEINS OF CARCINOEMBRYONAL ANTIGEN | 2005 |
|
RU2380375C2 |
